Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Autor: Nemat Ali, Fawaz Alasmari, Wael A. Alanazi, Nader S. AlGhamdi, Musaad A. Alshammari, Mohammed Alswayyed, Ali Alhoshani, Mohammed M. Alanazi, Homood M. As Sobeai, Naif O. Al-Harbi, Abdullah F. Alasmari

Publikováno v: Saudi Pharmaceutical Journal : SPJ
Saudi Pharmaceutical Journal, Vol 28, Iss 4, Pp 509-518 (2020)

Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide, a glucagon-like peptide 1 receptor agonist, showed potent c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b7230d338302facc1ca135fa14e87e
http://europepmc.org/articles/PMC7132601

Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways.

Autor: AlAsmari AF; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Ali N; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., AlAsmari F; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., AlAnazi WA; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., AlShammari MA; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Al-Harbi NO; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Alhoshani A; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., As Sobeai HM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., AlSwayyed M; Department of Pathology, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia., AlAnazi MM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., AlGhamdi NS; Department of Pharmacy Services, Prince Mohammed Bin Abdulaziz Hospital, Riyadh 14214, Saudi Arabia.

Publikováno v: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2020 Apr; Vol. 28 (4), pp. 509-518. Date of Electronic Publication: 2020 Mar 19.